Compare GlobalFoundries Inc. Ordinary Shares (GFS) vs Merck & Co., Inc. (MRK) Price & Performance

GlobalFoundries Inc. Ordinary SharesTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

GlobalFoundries Inc. Ordinary Shares vs Merck & Co., Inc. — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $50.4 (market cap $26.80B), while Merck & Co., Inc. trades at $142.3 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 13.1× GlobalFoundries Inc. Ordinary Shares's market cap, and Merck & Co., Inc. pays the higher dividend (2.38%). Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 0 Days and Merck & Co., Inc. for 98 Days on average.

	GFS	MRK
Market Cap	$26.80B	$352.29B
Volume	2,967,337	6,348,796
Sector	Technology	Health
52-Week High	$89.96	$156.43
52-Week Low	$32.24	$82.49
Typical Hold Time	0 Days	98 Days
Enterprise Value	$26.09B	$399.05B
Dividend Yield	1%	2.38%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GlobalFoundries Inc. Ordinary Shares

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.

The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GFS

51% Buy49% Sell

Avg holding period · 0 Days

MRK

18% Buy82% Sell

Avg holding period · 98 Days

Top news

Latest headlines on both assets

GFS

GlobalFoundries shares rise 3% on $2B deal with TSMC to boost US advanced chip packaging.Proactive Investors · 22 hours agoBullish GlobalFoundries partners with TSMC to build US silicon interposer supply for AI chip packaging, $2B deal.GlobeNewsWire · 1 day agoBullish View details →

MRK

Global DPP-4 inhibitors market to grow to $15.5B by 2032, driven by type 2 diabetes demand and generics expansion.PRNewsWire · 18 hours agoNeutral HP, Merck, and Seagate paid dividends on Oct 7, with Merck leading in per-share payout and HP offering the highest yield.24/7 Wall Street · 1 day agoBullish Dutch court blocks Merck's Keytruda SC sales in Europe for patent infringement.PRNewsWire · 2 days agoNeutral View details →

About GlobalFoundries Inc. Ordinary Shares

GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.